@article{Gama_Lima_Dangoni Filho_Peres_2020, title={A framework for decision making of migraine treatment with anti- CGRP monoclonal antibodies: a guide for real-world practice and public policies}, volume={11}, url={https://headachemedicine.com.br/index.php/hm/article/view/414}, DOI={10.48208/HeadacheMed.2020.20}, abstractNote={<p>Anti-CGRP monoclonal antibodies have been developed for migraine preventive treatment. There is evidence of good efficacy and safety of these medications; however, cost is a factor that interferes with the choice of treatment. This paper proposes a framework in order to better assist the decision-making processes on the use of these drugs in developing countries without coverage of health care costs for migraine. The framework was built after reviewing phase II and III studies on episodic and chronic migraine treatment with erenumab, galcanezumab and fremanezumab.</p>}, number={3}, journal={Headache Medicine}, author={Gama, Reinilza Nunes da and Lima, Thaiza Agostini Córdoba de and Dangoni Filho, Iron and Peres, Mario Fernando Prieto}, year={2020}, month={Sep.}, pages={72–76} }